Harpoon Therapeutics, Inc. Banner Image

Harpoon Therapeutics, Inc. has reached its limit for free report views

Work for Harpoon Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Harpoon Therapeutics, Inc.

  • Ticker HARP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Harpoon Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cellsMore. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the second half of 2020.
Harpoon Therapeutics, Inc.

Most Recent Annual Report

Harpoon Therapeutics, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Harpoon Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports